Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44358   clinical trials with a EudraCT protocol, of which   7384   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,358 result(s) found. Displaying page 2,087 of 2,218.
    «« First « Previous 2083  2084  2085  2086  2087  2088  2089  2090  2091  Next» Last»»
    EudraCT Number: 2020-005266-34 Sponsor Protocol Number: UX701-CL301 Start Date*: 2022-02-11
    Sponsor Name:Ultragenyx Pharmaceutical Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Multicenter, Seamless, Adaptive, Safety, Dose-finding, and Phase 3 Clinical Study of UX701 AAV-mediated Gene Transfer for the Treatment of Wilson Dis...
    Medical condition: Wilson disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10047988 Wilson's disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003369-37 Sponsor Protocol Number: D9077C00001 Start Date*: 2022-04-14
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable, Early-stage (II to IIIA) Non-small Cell Lung Cancer (NeoCOAST-2)
    Medical condition: Resectable, Early-stage (II to IIIA) Non-small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029518 Non-small cell lung cancer stage II PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) PT (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006462-20 Sponsor Protocol Number: CIC-10 Start Date*: 2022-11-30
    Sponsor Name:Instituto de Medicina Molecular
    Full Title: MESOTHERAPY IN LATERAL EPICONDYLITIS, A RANDOMIZED, DOUBLE- BLIND STUDY TO COMPARE THE EFFICACY OF MESOTHERAPY WITH PIROXICAM AND LIDOCAINE VERSUS INTRADERMAL DRY NEEDLING, IN THE TREATMENT OF LATE...
    Medical condition: lateral epicondylitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001076-11 Sponsor Protocol Number: CTQJ230A12301 Start Date*: 2019-12-19
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with establishe...
    Medical condition: Cardiovascular Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10051614 Arteriosclerotic cardiovascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) GB (GB - no longer in EU/EEA) DK (Trial now transitioned) SK (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) PT (Trial now transitioned) SE (Trial now transitioned) NL (Ongoing) BG (Trial now transitioned) BE (Trial now transitioned) NO (Trial now transitioned) SI (Trial now transitioned) RO (Trial now transitioned) IS (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003613-19 Sponsor Protocol Number: APHP210303 Start Date*: 2021-12-07
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: AbataCept for the treatment of immune-cHeckpoint inhibitors induced mYocarditiS
    Medical condition: All adult patients with cancer (all cancer types) treated by immune checkpoint inhibitors (anti-PD1, anti-PDL1, anti-CTLA4 monotherapies or combination) and presenting drug-induced myocarditis. The...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004863-14 Sponsor Protocol Number: NN9389-4606 Start Date*: 2021-12-07
    Sponsor Name:Novo Nordisk A/S
    Full Title: Investigation of the safety and efficacy of semaglutide s.c. in combination with NNC0480-0389 in participants with type 2 diabetes – a dose finding study
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) HU (Completed) GR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-002551-42 Sponsor Protocol Number: HS0004 Start Date*: 2020-07-10
    Sponsor Name:UCB Biopharma SRL
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
    Medical condition: Hidradenitis Suppurativa (HS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Completed) FR (Completed) GB (GB - no longer in EU/EEA) HU (Completed) CZ (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2005-002880-98 Sponsor Protocol Number: CRO-04-62 / GP/C/03/PRO Start Date*: 2005-11-25
    Sponsor Name:GP-Pharm s.a.
    Full Title: Efficacy and safety of a new Leuprolide acetate 3.75 mg depot formulation, GP-Pharm s.a., when given as palliative treatment to prostate cancer patients
    Medical condition: prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    6.0 10007113 LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Completed) GB (Completed) CZ (Completed) HU (Completed) IT (Completed) DE (Completed) SK (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003481-42 Sponsor Protocol Number: 291-417 Start Date*: 2006-04-21
    Sponsor Name:Protein Design Labs, Inc
    Full Title: A Randomized, Double-blind, Multicenter Study of Visilizumab versus Placebo in Subjects with Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study
    Medical condition: Intravenous steroid-refractory ulcerative colitis (IVSR-UC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) HU (Prematurely Ended) CZ (Completed) DE (Prematurely Ended) AT (Prematurely Ended) IE (Completed) ES (Ongoing) GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-003662-41 Sponsor Protocol Number: MW-2004-11-02 Start Date*: 2005-11-24
    Sponsor Name:MediWound Ltd
    Full Title: Enzymatic Debridement in Burns Patients (Children & Adults): A Comparison to Standard of Care (Protocol MW 2004-11-02)
    Medical condition: Burn wounds defined as deep partial thickness or full thickness thermal burns.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) SK (Completed) PT (Completed) CZ (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-003698-42 Sponsor Protocol Number: D1250C00012 Start Date*: 2008-11-21
    Sponsor Name:AstraZeneca AB
    Full Title: A controlled, randomised, double-blind, double-dummy, parallel-group, phase III, multicenter study to evaluate efficacy and safety of the oral direct thrombin inhibitor AZD0837 compared to warfarin...
    Medical condition: the prevention of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (AF)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003658 Atrial fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) SK (Completed) DE (Completed) HU (Prematurely Ended) ES (Prematurely Ended) FR (Ongoing) DK (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003447-11 Sponsor Protocol Number: C-145-04 Start Date*: 2017-10-27
    Sponsor Name:Iovance Biotherapeutics, Inc.
    Full Title: A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma
    Medical condition: Recurrent, metastatic, or persistent Cervical Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10008229 Cervical cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Prematurely Ended) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-004943-12 Sponsor Protocol Number: S308.3.010 Start Date*: 2008-11-24
    Sponsor Name:Solvay Pharmaceuticals B.V.
    Full Title: The Rubens Study: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo and Pramipexole Controlled Study to Explore the Efficacy, Tolerability and Safety of Different Doses and Titration...
    Medical condition: Early Stage Parkinson’s Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011621-14 Sponsor Protocol Number: CAIN457A2202E1 Start Date*: 2009-11-12
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 52-week open label extension study to evaluate the safety and tolerability of AIN457 (anti IL-17 monoclonal antibody) in patients with moderate to severe Crohn’s disease
    Medical condition: Moderate to severe Crohn's disease (CDAI ≥ 220 and ≤450)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011401 Crohn's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-005172-26 Sponsor Protocol Number: D-AF-09 Start Date*: 2010-09-06
    Sponsor Name:S.L.A. Pharma (UK) Ltd
    Full Title: A Randomised, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Diltiazem Hydrochloride Cream in Subjects with Anal Fissure
    Medical condition: Symptomatic relief of pain related to anal fissure (AF).
    Disease: Version SOC Term Classification Code Term Level
    12.1 10002153 Anal fissure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) LT (Completed) ES (Completed) BG (Completed) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016782-28 Sponsor Protocol Number: GMIHO-009/2009/AG52 Start Date*: 2010-09-15
    Sponsor Name:GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH
    Full Title: Panitumimab in combination with radiotherapy in patients with locally advanced RAS wildtype rectal cancer (clinical stages II and III)
    Medical condition: Locally advanced RAS wildtype rectal cancer (clinical stage II and III)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038050 Rectal cancer stage III PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038049 Rectal cancer stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001187-21 Sponsor Protocol Number: SCRM-001 Start Date*: 2011-11-28
    Sponsor Name:University of Zurich
    Full Title: A Phase I/II, Open Monocentric Study To Evaluate The Safety And Efficacy Of An Autologous Tissue-Engineered Vascular Graft In Peadiatric Patients Requiring Reconstruction Of Right Ventricle Outflow...
    Medical condition: functional single ventricle physiology functional single left ventricle functional single right ventricle functional single biventricle
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10040729 Single ventricle LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-006253-29 Sponsor Protocol Number: CLI00070 Start Date*: 2012-07-31
    Sponsor Name:Cerus Corporation
    Full Title: A Randomized Controlled Double-Blind Phase 3 Study to Assess Characteristics of S-303 Treated RBC Components and Evaluate Safety and Efficacy in Patients Requiring Transfusion Support of Acute Anemia
    Medical condition: Acute anemia secondary to cardiovascular surgery.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022117 - Injury, poisoning and procedural complications 10054312 Anemia postoperative LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001285-10 Sponsor Protocol Number: CA209-171 Start Date*: 2015-05-15
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: An Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) Monotherapy in Subjects with Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) who Have Received at...
    Medical condition: Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SE (Completed) DE (Completed) FI (Completed) DK (Completed) PT (Completed) ES (Ongoing) AT (Completed) GB (GB - no longer in EU/EEA) IE (Completed) GR (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-002854-37 Sponsor Protocol Number: CRFB002DDE26 Start Date*: 2014-12-23
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 12-months, randomized, VA-assessor blinded, multicenter, controlled phase IV trial to investigate non-inferiority of two treatment algorithms (discretion of the investigator vs. pro re nata) of 0...
    Medical condition: Visual impairment due to diabetic macular edema
    Disease: Version SOC Term Classification Code Term Level
    19.0 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2083  2084  2085  2086  2087  2088  2089  2090  2091  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Sep 04 21:47:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA